Ponericin
An ant-venom antimicrobial peptide family — linear helical peptides that punch through microbial membranes, including drug-resistant bacteria. Research compounds, not drugs
Ponericins come from the venom of the ant, where they help the insect subdue prey and fight infection. They are linear, strongly cationic peptides that fold into an amphipathic helix on contact with a membrane — no disulfide bonds, just a simple helix with its water-liking and fat-liking faces on opposite sides. That shape lets a ponericin insert into and break a microbial membrane, giving it broad, fast activity against bacteria (including drug-resistant hospital pathogens), fungi and biofilms; one member also slips inside the cell and binds its DNA. Because they are relatively gentle on host cells, ponericins and their engineered analogs have drawn interest as wound-healing anti-infectives. Ponericins are research peptides; they are not approved medicines and have not been given to people as an approved treatment.
No established human dose Details ↓
Recommended Dosing
No established human dose
Ponericins are ant-venom research peptides; no ponericin is an approved treatment. The work here is in microbes, cultured cells and animals, often with engineered analogs, at experimental amounts that do not carry over to people, so no amount is printed here.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Ant venom is a rich source of antimicrobial peptides, and the ponericins are the best-studied example. First isolated in 2001 from the venom of the ant Pachycondyla goeldii, they form several related groups (the W, G, L and Q families) of short, linear, strongly cationic peptides, around twenty-seven to thirty-four amino acids long. Unlike many antimicrobial peptides they carry no disulfide bonds; instead each folds into a simple amphipathic helix — water-liking residues along one face, fat-liking residues along the other — when it meets a membrane. Close relatives, the dinoponeratoxins, occur in the venom of the giant ant Dinoponera quadriceps, and strikingly an identical peptide turns up in the blood of the silkworm.
The ponericin mechanism is membrane disruption. The helix binds the microbial surface, inserts, and permeabilises the cell, giving broad and rapid activity. A silkworm peptide identical to the ant-venom ponericin disrupted the membranes of drug-resistant hospital pathogens, confirmed by microscopy, broke up their biofilms, and did not damage red blood cells. Synthetic ponericin-like peptides from giant-ant venom were bactericidal against carbapenem-resistant Acinetobacter, Klebsiella and Pseudomonas and worked together with conventional antibiotics, again with low toxicity to blood cells, and the same kind of peptide showed broad, rapid antifungal (anti-Candida) activity in concert with antifungal drugs.
Ponericins have proven to be good scaffolds for engineering. Rationally designed peptides based on ponericin-W1 killed Gram-negative bacteria without provoking resistance over many generations and sped wound healing in a mouse skin-infection model — a combination of potency, resistance-resilience and tissue repair that is attractive for anti-infective dressings. Detailed structure-activity work on ponericin L1 showed that its helix, its water-to-fat balance and its amino-acid makeup jointly govern how it engages a membrane and how potent it is, mapping the levers a designer can pull.
At least one ponericin does more than break membranes. Beyond permeabilising the cell, ponericin W1 penetrates fungal cells, binds their genomic DNA and slips between the strands of the double helix, shutting down the cell's DNA and RNA synthesis — a second, intracellular route to killing that adds to the membrane attack.
Through all of this, ponericins remain research peptides. No ponericin is an approved medicine, and material sold online under this name is an unregulated research chemical. Nothing here is a dose or a therapy; this page records what the published science says.
Mechanism of Action
Ponericins are linear, cationic, amphipathic alpha-helical ant-venom antimicrobial peptides (~27-34 aa, no disulfide bonds) that insert into and permeabilise microbial membranes — broad and fast against bacteria (including drug-resistant ones), fungi and biofilms. At least one (W1) also enters the cell and binds DNA, and their low host toxicity makes them wound-healing leads.
Ant-venom host defense
A ~27-34 residue linear cationic peptide that folds into an amphipathic helix, from the venom of Pachycondyla/Neoponera goeldii; relatives occur in Dinoponera and silkworm (PMIDs 34792624, 32861765).
Membrane disruption
Inserts into and permeabilises microbial membranes, giving broad, rapid activity against bacteria (including drug-resistant hospital pathogens), fungi and biofilms, with low red-cell toxicity (PMIDs 36109567, 32861765).
DNA binding and wound healing
Ponericin W1 also enters cells and binds DNA; designed ponericin-W1 analogs resist bacterial resistance and speed wound healing in mice (PMIDs 34441696, 35861280).
Published Research
These are studies of ponericins read from their PubMed records on November 8, 2026: a silkworm ponericin-like peptide against drug-resistant Pseudomonas; designed ponericin-W1 analogs that heal wounds in mice; a ponericin-like peptide against carbapenem-resistant bacteria; a ponericin-like antifungal; a structure-activity study of ponericin L1; and ponericin W1 binding genomic DNA. The evidence is in microbes, cells and animals; no ponericin is an approved treatment.
A silkworm ponericin-like peptide against drug-resistant Pseudomonas
A silkworm peptide identical to the ant-venom ponericin (Bm-ponericin-L1), made in response to Pseudomonas infection, disrupted the membranes of drug-resistant hospital pathogens (confirmed by microscopy), broke up their biofilms, and did not damage red blood cells (an in-vitro study).
Designed ponericin-W1 analogs heal wounds in mice
Rationally designed peptides based on ponericin-W1 killed Gram-negative bacteria without provoking resistance over many generations and sped wound healing in a mouse skin-infection model, combining potency with tissue repair (a preclinical study).
A ponericin-like peptide against carbapenem-resistant bacteria
A synthetic ponericin G-like peptide from giant-ant venom (sDq-3162) was bactericidal and worked together with antibiotics against carbapenem-resistant Acinetobacter, Klebsiella and Pseudomonas, with low toxicity to red blood cells (an in-vitro study).
A ponericin-like antifungal
A ponericin-like peptide from giant-ant venom showed broad, rapid activity against Candida through membrane disruption and worked together with conventional antifungal drugs (an in-vitro study).
What makes ponericin L1 work
Systematic residue changes showed that ponericin L1's helix, its balance of water-liking and fat-liking residues, and its amino-acid makeup jointly govern how it engages a membrane and how potent it is — mapping the levers for designing better analogs (a structure-activity study).
Ponericin W1 binds genomic DNA
Beyond breaking membranes, ponericin W1 penetrates fungal cells, binds their genomic DNA and slips between the strands of the double helix, shutting down DNA and RNA synthesis — a second, intracellular route to killing (an in-vitro study).
No Established Human Dose
Ponericins are ant-venom research peptides; no ponericin is an approved treatment. The work here is in microbes, cultured cells and animals, often with engineered analogs, at experimental amounts that do not carry over to people, so no amount is printed here.
What this rests on: PMID 36109567, PMID 35861280, PMID 32861765.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Ponericin is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
Unknown: no human dose of Ponericin has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Ponericin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Ponericin stays intact once mixed.
How it is taken
Unknown: with no established human dose, there is no established way of taking Ponericin. What the human studies gave and how is set out under No Established Human Dose.
What to expect, and when
How long it stays in the body: a half-life of not established for humans; a short linear peptide, engineered analogs improve stability. After about five half-lives almost none is left.
When effects appear: unknown; no source on this page gives a time to effect for Ponericin. Results reported in the studies are under Published Research.
Source: half-life: PMID 35861280.
Side effects, and when to stop or get help
From the Side Effects section: No approved-treatment human safety data exist for ponericins; Ponericins disrupt membranes but are relatively gentle on host cells, with low red-cell toxicity in the lab (PMIDs 36109567, 32861765) — research findings, not approved-drug data; They come from ant venom and at least one also binds DNA (PMID 34441696), effects to weigh in any development; Material sold online as 'ponericin' is an unregulated research chemical of unverified content. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Ponericin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“Ponericins are research peptides and no ponericin is an approved treatment, so there is no established human safety profile; the points below reflect that status and their biology”).
Interactions
Unknown: a PubMed search for human interaction studies of Ponericin (reviewed 2026-11-08) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Ponericin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Research Chemical (Not approved drugs: Drugs@FDA and the openFDA label endpoint hold no record, and FDA GSRS and ChEMBL hold no approved-drug record for ponericin (searched November 8, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
Ponericins are research peptides and no ponericin is an approved treatment, so there is no established human safety profile; the points below reflect that status and their biology.
Contraindications & Cautions
Ponericins have no approved use and no label. These points reflect their research status.
Legal Status
Ponericins are ant-venom antimicrobial peptides used as research compounds; they are not approved drugs in any country.
Frequently Asked Questions
?What is ponericin?
A family of antimicrobial peptides from ant venom, first isolated in 2001 from the ant Pachycondyla goeldii. Each is a short (~27-34 amino acid) linear, cationic peptide that folds into an amphipathic helix with no disulfide bonds (PMID 34792624).
?How does it work?
Mainly by inserting into and breaking microbial membranes, giving broad, fast activity against bacteria (including drug-resistant ones), fungi and biofilms; ponericin W1 also enters cells and binds their DNA (PMIDs 32861765, 34441696).
?Is it approved or available to buy?
No. Ponericins are not approved medicines, have no FDA application or label, and are approved nowhere. Material sold online as a ponericin is an unregulated research chemical. Grey Peptides lists no sellers and recommends no source; this page records the published science.
References
- [mechanism] Nesa J, et al. "Antimicrobial potential of a ponericin-like peptide isolated from Bombyx mori L. hemolymph in response to Pseudomonas aeruginosa infection." Sci Rep, 2022;12(1):15493. PMID: 36109567.
- [animal] Lv S, et al. "Highly selective performance of rationally designed antimicrobial peptides based on ponericin-W1." Biomater Sci, 2022;10(17):4848-4865. PMID: 35861280.
- [mechanism] Dodou Lima HV, et al. "Antimicrobial activity of synthetic Dq-3162, a 28-residue ponericin G-like dinoponeratoxin from the giant ant Dinoponera quadriceps venom, against carbapenem-resistant bacteria." Toxicon, 2020;187:19-28. PMID: 32861765.
- [mechanism] Dodou Lima HV, et al. "Antifungal In Vitro Activity of Pilosulin- and Ponericin-Like Peptides from the Giant Ant Dinoponera quadriceps and Synergistic Effects with Antimycotic Drugs." Antibiotics (Basel), 2020;9(6). PMID: 32585881.
- [review] Schifano NP, et al. "Investigation of the Role of Hydrophobic Amino Acids on the Structure-Activity Relationship in the Antimicrobial Venom Peptide Ponericin L1." J Membr Biol, 2022;255(4-5):537-551. PMID: 34792624.
- [mechanism] Zhang H, et al. "Interaction of Antimicrobial Peptide Ponericin W1, Thanatin, and Mastatopara-S with Geotrichum citri-aurantii Genomic DNA." Foods, 2021;10(8). PMID: 34441696.
- [other] Ponericins are alpha-helical antimicrobial peptides from the venom of the ant Pachycondyla (Neoponera) goeldii, first isolated and named by Orivel and colleagues (J Biol Chem, 2001). Their structure, antimicrobial mechanism and engineered analogs are described in the studies carded on this page (read November 8, 2026).
- [other] US FDA, Drugs@FDA and the openFDA label endpoint, searched November 8, 2026: no application and no label record for ponericin. It is an ant-venom research peptide family, not an approved drug; FDA GSRS and ChEMBL hold no approved-drug record for it.
Sources & Citations
The six studies carded above were read from their PubMed records on November 8, 2026. Ponericins' ant-venom origin, their linear cationic amphipathic alpha-helical structure, their membrane-permeabilising antimicrobial mechanism against drug-resistant bacteria, fungi and biofilms, the DNA binding of ponericin W1, and the wound-healing of designed ponericin-W1 analogs are from the studies carded here; the family was first isolated from Pachycondyla goeldii venom by Orivel and colleagues (2001). The absence of US approval or a drug record from Drugs@FDA, openFDA, FDA GSRS and ChEMBL was checked the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.